The Myeloproliferative Disorders Research Consortium (MPD-RC) focuses on the Philadelphia chromosome negative myeloproliferative neoplasms (MPN) including polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) and has the following goals 1) Establish a multi-institutional international research group which will coordinate and facilitate basic and clinical research dealing with the cellular and genetic basis of the MPN. 2) Establish a multi-institutional Clinical Consortium to enable uniform, high volume sample collection, storage and distribution. 3) Perform rationally designed clinical trials in patients with MPN at multiple institutions. 4) Maintain an interactive website for MPD Consortium investigators, a sophisticated international tissue bank and an on-line database that will allow for integration of basic and clinical research. This unique interactive relationship between talented basic researchers and clinical scientists will permit the MPD-RC to develop novel clinical treatment programs for MPN and to identify specific biomarkers that will be useful as indicators of therapeutic response and/or risk reduction. This program has six major projects: Project 1: Genetic Basis of Polycythemia Vera, Project Leader: J. T. Prchal;Project 2: A Novel Murine Model for MPN: Pathology and Therapy of NF-E2 Overexpression, Project Leader: H. L. Pahl;Project 3: Animal Models of Polycythemia Vera, Project Leader: J. L. Spivak;Project 4: Mouse Models of Myelofibrosis, Project Leader: A. Migliaccio;Project 5: Abnormal Stem Cell Trafficking in Myelofibrosis, Project Leader: R. Hoffman;Project 6: MPD Clinical Consortium which will pursue clinical trials in PV. ET and PMF, Project Leader: Lewis Silverman. The 6 projects will be supported by 3 cores: Core A, Administrative Core, PI: R. Hoffman;Core B: Biostatistics and Data Management;PI: J. A. Goldberg and Co-PI R. Marchioli;Core C;Tissue Bank, PI: R. Weinberg. These unique interactions between clinical and laboratory investigators which are interwoven within the MPD-RC will ultimately result in improved understanding of the pathobiology of the MPN as provide well improved strategies that will assist in the management of MPN patients.

Public Health Relevance

The MPD-RC is a group of basic and clinical scientists who are experts in a variety of disciplines pertaining to the MPN including polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). The overall goal of the MPD-RC is to increase our knowledge of the origins of the MPN with the hope of generating the foundation for the development of novel therapeutic strategies for the treatment of MPN patients

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-J (O1))
Program Officer
Merritt, William D
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Icahn School of Medicine at Mount Sinai
Internal Medicine/Medicine
Schools of Medicine
New York
United States
Zip Code
Wang, Xiaoli; Cho, Sool Yeon; Hu, Cing Siang et al. (2015) C-X-C motif chemokine 12 influences the development of extramedullary hematopoiesis in the spleens of myelofibrosis patients. Exp Hematol 43:100-9.e1
Wehrle, Julius; Pahl, Heike L; von Bubnoff, Nikolas (2014) Ponatinib: a third-generation inhibitor for the treatment of CML. Recent Results Cancer Res 201:99-107
Spivak, Jerry L; Considine, Michael; Williams, Donna M et al. (2014) Two clinical phenotypes in polycythemia vera. N Engl J Med 371:808-17
Dickinson, Rachel E; Milne, Paul; Jardine, Laura et al. (2014) The evolution of cellular deficiency in GATA2 mutation. Blood 123:863-74
Rondelli, Damiano; Goldberg, Judith D; Isola, Luis et al. (2014) MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood 124:1183-91
Rheinemann, Lara; Seeger, Thalia S; Wehrle, Julius et al. (2014) NFE2 regulates transcription of multiple enzymes in the heme biosynthesis pathway. Haematologica 99:e208-10
Kapralova, Katarina; Lanikova, Lucie; Lorenzo, Felipe et al. (2014) RUNX1 and NF-E2 upregulation is not specific for MPNs, but is seen in polycythemic disorders with augmented HIF signaling. Blood 123:391-4
Wang, L; Swierczek, S I; Drummond, J et al. (2014) Whole-exome sequencing of polycythemia vera revealed novel driver genes and somatic mutation shared by T cells and granulocytes. Leukemia 28:935-8
Ye, Zhaohui; Liu, Cyndi F; Lanikova, Lucie et al. (2014) Differential sensitivity to JAK inhibitory drugs by isogenic human erythroblasts and hematopoietic progenitors generated from patient-specific induced pluripotent stem cells. Stem Cells 32:269-78
Essig, Aitomi; Duque-Afonso, Jesus; Schwemmers, Sven et al. (2014) The AML1/ETO target gene LAT2 interferes with differentiation of normal hematopoietic precursor cells. Leuk Res 38:340-5

Showing the most recent 10 out of 116 publications